Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Down 91.8% in August

by · The Cerbat Gem

Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) saw a large decline in short interest in August. As of August 14th, there was short interest totaling 39 shares, a decline of 91.8% from the July 30th total of 474 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. Currently, 0.0% of the shares of the company are short sold.

Basilea Pharmaceutica Stock Performance

Shares of BPMUF stock remained flat at $77.40 during trading hours on Tuesday. The firm has a 50-day moving average price of $63.19 and a two-hundred day moving average price of $66.89. Basilea Pharmaceutica has a one year low of $59.29 and a one year high of $77.40. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.11 and a quick ratio of 4.68.

Basilea Pharmaceutica Company Profile

(Get Free Report)

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.

See Also